Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 98-107

  Shevchenko, Ivan ^a,b,c   Karakhanova, Svetlana ^a   Soltek, Sabine ^a   Link, Julia ^a   Bayry, Jagadeesh ^d   Werner, Jens ^a   Umansky, Viktor ^b,c   Bazhin, Alexandr V ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

gemcitabine; orthotopic mouse tumor model; pancreatic adenocarcinoma; regulatory T cells

Indexed keywords

GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DIVISION; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG TARGETING; EFFECTOR CELL; EXPERIMENTAL MOUSE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DEOXYCYTIDINE; FLOW CYTOMETRY; LYMPHOCYTE COUNT; MICE; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84876678701     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27990     Document Type: Article

References (53)

1. Warshaw AL, Fernandez-del Castillo C,. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
2. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
3. Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005; 128: 1606-25.
4. Dougan M, Dranoff G,. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
5. Curiel TJ,. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-74.
6. Josefowicz SZ, Lu LF, Rudensky AY,. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-64.
7. Erdman SE, Poutahidis T,. Cancer inflammation and regulatory T cells. Int J Cancer 2010; 127: 768-79.
8. Wei S, Kryczek I, Zou W,. Regulatory T-cell compartmentalization and trafficking. Blood 2006; 108: 426-31.
9. Bayry J, Tchilian EZ, Davies MN, et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA 2008; 105: 10221-6.
10. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 919-29.
11. Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006; 66: 4488-95.
12. Bilate AM, Lafaille JJ,. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012; 30: 733-58.
13. Zhou G, Levitsky HI,. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007; 178: 2155-62.
14. Pasquier E, Kavallaris M, Andre N,. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455-65.
15. Serba S, Schmidt J, Wentzensen N, et al. Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut 2008; 57: 344-51.
16. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-80.
17. Pere H, Montier Y, Bayry J, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118: 4853-62.
18. Yang Y, Karakhanova S, Soltek S, et al. In vivo immunoregulatory properties of the novel mitochondria-targeted antioxidant SkQ1. Mol Immunol 2012; 52: 19-29.
19. Sprent J,. Immunological memory. Curr Opin Immunol 1997; 9: 371-9.
20. Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenvironment. Int J Cancer 2007; 121: 699-705.
21. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-61.
22. Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009; 119: 2648-62.
23. Klein L, Khazaie K, von Boehmer H,. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 2003; 100: 8886-91.
24. Caretto D, Katzman SD, Villarino AV, et al. Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol 2010; 184: 30-4.
25. Nishikawa H, Kato T, Tawara I, et al. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 2005; 175: 4433-40.
26. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev 2009; 9: 162-74.
27. Matthaios D, Zarogoulidis P, et al. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 2011; 81: 259-72.
28. Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012; 41: 409-15.
29. Nishikawa H, Sakaguchi S,. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-67.
30. Muller-Berghaus J, Ehlert K, Ugurel S, et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 2006; 66: 5997-6001.
31. Feuerer M, Beckhove P, Garbi N, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9: 1151-7.
32. Joncker NT, Helft J, Jacquet A, et al. Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion. Cancer Res 2006; 66: 5443-51.
33. Read S, Mauze S, Asseman C, et al. CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 1998; 28: 3435-47.
34. Huehn J, Siegmund K, Lehmann JC, et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004; 199: 303-13.
35. Fisson S, Darrasse-Jeze G, Litvinova E, et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 2003; 198: 737-46.
36. Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006; 13: 1252-8.
37. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007; 27: 145-59.
38. Jacobs C, Duewell P, Heckelsmiller K, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011; 128: 897-907.
39. Quezada SA, Peggs KS, Simpson TR, et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205: 2125-38.
40. Jacobs JF, Punt CJ, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010; 16: 5067-78.
41. Powell DJ, Jr., Attia P, Ghetie V, et al. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother 2008; 31: 189-98.
42. Hindley JP, Ferreira C, Jones E, et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011; 71: 736-46.
43. Moo-Young TA, Larson JW, Belt BA, et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother 2009; 32: 12-21.
44. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev 2008; 8: 59-73.
45. Nowak AK, Robinson BW, Lake RA,. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62: 2353-8.
46. Rettig L, Seidenberg S, Parvanova I, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011; 129: 832-8.
47. Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012; 41: 195-205.
48. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev 2010; 10: 490-500.
49. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336-44.
50. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-8.
51. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-8.
52. Sakamoto H, Kitano M, Suetomi Y, et al. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 2006; 41: 70-6.
53. Shibuya K, Oya N, Fujii T, et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol 2011; 34: 115-9.